U.S. Neuroblastoma Market Size, Share & Forecast 2026–2032

ID: MR-11900 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Neuroblastoma Therapeutics
  • ✓Market Size 2024: USD 0.32 billion
  • ✓Market Size 2032: USD 0.51 billion
  • ✓CAGR: 6.0%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Concentrated Anti-GD2 Revenue Pool: U.S. neuroblastoma revenue sits almost entirely with two anti-GD2 antibodies, United Therapeutics' Unituxin and Y-mAbs' Danyelza, while U.S. WorldMeds' Iwilfin now anchors maintenance. With roughly 700 new diagnoses annually, price per course and reimbursement pathway determine returns, not volume.
FINDING 02
Oral Maintenance Outgrows Frontline: Conventional wisdom treats frontline anti-GD2 induction as the growth engine, yet oral maintenance will add more U.S. patient-months by 2030. Iwilfin's oral format removes infusion-chair dependence, letting community practices and specialty pharmacies capture volume that hospital infusion centers have held.
ANALYST RECOMMENDATION

Analyst Recommendation — Secure Pediatric Oncology Partnerships: Entrants should secure Children's Oncology Group site partnerships and request Rare Pediatric Disease designation before 2026 trial enrollment opens. Early site access drives enrollment speed, and priority review eligibility protects exclusivity in a market below USD 0.5 billion.

Neuroblastoma in the U.S.: Market Overview

Neuroblastoma is the most common extracranial solid tumor in children, and the U.S. therapeutics market is a small, orphan-driven segment valued at an estimated USD 0.32 billion in 2024. The country records about 700 new cases annually, with most diagnoses before age five, which keeps patient volume low while per-course prices remain among the highest in pediatric oncology. Treatment cost concentrates in multi-cycle regimens spanning induction, consolidation, and maintenance phases.

Compared with the global market, which Europe and China shape through broader formularies and regional biosimilar activity, the U.S. market is defined by a narrow set of FDA-approved agents and a tightly networked treatment base. Most high-risk patients are managed within Children's Oncology Group member institutions, so commercial access depends on a limited pool of pediatric oncologists and their hospital formularies. This concentration makes institutional formulary committees the primary gatekeepers for every new agent.

Growth Drivers in U.S. Neuroblastoma Care

Three country-specific forces are expanding demand. First, the FDA approved Iwilfin (eflornithine) from U.S. WorldMeds in December 2023 for maintenance in high-risk patients who responded to prior multimodal therapy, creating the first oral post-consolidation option. Second, Danyelza (naxitamab-gqgk) from Y-mAbs received FDA approval in November 2020 for relapsed or refractory disease in bone or bone marrow, widening the infusion-based treatment pathway.

Third, the Childhood Cancer Data Initiative, authorized under the Childhood Cancer STAR Act, supports genomic profiling of pediatric tumors, improving MYCN and ALK testing that stratifies eligibility for targeted agents. Survival expansion adds further volume: five-year survival for high-risk disease remains near 50 percent, so each additional line of therapy sustains treatment demand across Children's Oncology Group sites nationwide.

Market Restraints and Entry Barriers

Entry is constrained by three barriers. First, the boxed warning on Danyelza covers serious infusion reactions and neurotoxicity, requiring hospital-based administration with monitoring infrastructure, which limits community oncology uptake and raises per-site operating costs. Second, anti-GD2 antibodies are typically reimbursed under the medical benefit through buy-and-bill arrangements, so payer utilization review and prior authorization delay treatment initiation for children.

Third, the Inflation Reduction Act's orphan drug exclusion has been broadened, yet Medicare price negotiation remains a planning risk for any product with multiple rare indications. Incumbents also hold structural advantages: United Therapeutics' Unituxin is embedded in established COG protocols, and the 340B program lets safety-net children's hospitals purchase at discounted prices, compressing realized net revenue for newcomers.

Market Opportunities in the U.S.

Oral maintenance is the clearest near-term opening. An estimated 350 high-risk patients are diagnosed each year, and a substantial share reach the post-consolidation phase where maintenance agents apply, creating a recurring treatment window of several months per patient. Entrants offering oral or home-administered formulations can serve families who cannot remain near infusion centers, particularly those outside major metropolitan areas.

Cell-based relapse therapies represent a second opening. GD2-targeted CAR-T programs at Memorial Sloan Kettering have advanced into clinical study, and companion diagnostics for GD2 expression and MYCN amplification create a diagnostic revenue stream alongside therapy. Biomarker testing services sold to hospital laboratories and reference labs require lower capital commitment than full therapy launches.

Market at a Glance

IndicatorDetail
Market Size 2024USD 0.32 billion
Market Size 2032USD 0.51 billion
Growth Rate (CAGR)6.0%
Most Critical Decision FactorReimbursement access for low-volume, high-price pediatric biologics
Largest RegionNortheast United States
Competitive StructureConcentrated, with few approved agents and specialty biopharma leadership

Leading Market Participants

  • Y-mAbs Therapeutics
  • United Therapeutics
  • U.S. WorldMeds
  • Children's Oncology Group
  • Memorial Sloan Kettering Cancer Center
  • St. Jude Children's Research Hospital
  • Children's Hospital of Philadelphia
  • Cardinal Health
  • McKesson
  • Cencora

Regulatory and Policy Environment

The FDA's Center for Drug Evaluation and Research reviews neuroblastoma products under the Orphan Drug Act of 1983, which grants seven years of market exclusivity for approved indications. The Rare Pediatric Disease Priority Review Voucher program awards a transferable voucher upon approval of a designated product, while the Pediatric Research Equity Act requires pediatric study plans. Standard review runs ten months from filing, and priority review runs six months.

The Centers for Medicare and Medicaid Services governs reimbursement, with infused antibodies paid under Medicare Part B and oral agents under Part D, alongside rebates under the Medicaid Drug Rebate Program. The Office of Inspector General monitors 340B compliance, while the National Cancer Institute and the Children's Oncology Group set treatment standards that payers reference. Post-marketing pediatric commitments must be scheduled before launch.

Long-Term Outlook for Neuroblastoma in the U.S.

By 2032 the U.S. neuroblastoma therapeutics market is projected to reach USD 0.51 billion, growing at a 6.0% CAGR from the 2025 base year. Growth will be led by oral maintenance and expanded relapse protocols, while anti-GD2 antibodies retain the largest revenue share throughout the forecast period. Price discipline under Medicare and 340B constraints remains the central financial variable.

Competition will intensify as cell-based therapies move toward registration, shifting share toward developers with established COG trial relationships. Diagnostic and genomic testing services will grow alongside therapeutics, integrating biomarker selection into treatment pathways. Entrants that secure site access and reimbursement pathways early will capture the most durable share of this concentrated market.

Frequently Asked Questions

Secure orphan drug designation and Rare Pediatric Disease designation before filing a New Drug Application with FDA's Center for Drug Evaluation and Research. Priority review provides a six-month clock, compared with ten months under standard review.
Children's Oncology Group member institutions and large pediatric hospital formularies control most high-risk treatment decisions. Winning placement on these formularies requires sustained engagement with pharmacy and therapeutics committees.
The U.S. records about 700 new cases annually, with an estimated 350 high-risk patients eligible for intensive multimodal therapy. Maintenance and relapse populations add recurring volume beyond initial diagnosis.
Infused antibodies are reimbursed under Medicare Part B and commercial medical benefits, while oral maintenance agents fall under Medicare Part D and pharmacy benefits. Entrants must build separate market access strategies for each route.
Licensing arrangements with established pediatric oncology commercial teams reduce launch risk in a small, concentrated market. Co-development agreements with Children's Oncology Group sites also accelerate enrollment and real-world evidence generation.

Market Segmentation

By Therapy Class
  • Anti-GD2 Monoclonal Antibodies
  • Oral Maintenance Agents
  • Retinoid Differentiation Therapy
  • GD2-Targeted Cell Therapies
By End User
  • Pediatric Oncology Centers
  • Community Oncology Practices
  • Specialty Pharmacies
  • Clinical Trial Sites

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Neuroblastoma - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Therapy Class Insights
4.1 Anti-GD2 Monoclonal Antibodies
4.2 Oral Maintenance Agents
4.3 Retinoid Differentiation Therapy
4.4 GD2-Targeted Cell Therapies
4.5 Others
Chapter 05 End User Insights
5.1 Pediatric Oncology Centers
5.2 Community Oncology Practices
5.3 Specialty Pharmacies
5.4 Clinical Trial Sites
5.5 Others
Chapter 06 Competitive Landscape
6.1 Market Players
6.2 Leading Market Participants
6.2.1 Y-mAbs Therapeutics
6.2.2 United Therapeutics
6.2.3 U.S. WorldMeds
6.2.4 Children's Oncology Group
6.2.5 Memorial Sloan Kettering Cancer Center
6.2.6 St. Jude Children's Research Hospital
6.2.7 Children's Hospital of Philadelphia
6.2.8 Cardinal Health
6.2.9 McKesson
6.2.10 Cencora
6.3 Regulatory Environment
6.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.